| Date | Title | Description |
| 28.08.2026 | Akeso 2026 Interim Results: Strong Commercialization Momentum; IO2.0+ Global Strategy Redefining Clinical Standards; Bispecific Advancement in ADC, I&I and Alzheimer's | HONG KONG, Aug. 28, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced its 2026 interim results. During the reporting period, the Company achieved record-high drug sales revenue, further adva... |
| 03.08.2026 | NYU Langone and Dana-Farber Co-Develop Solavia Decision Suite | What You Should Know
NYU Langone Health and Dana-Farber Cancer Institute have co-developed the Solavia Decision Suite, an oncology decision support platform designed to deliver precise, evidence-based, and standardized care delivery at scal... |
| 20.07.2026 | Marengo Secures ESMO 2026 Oral Presentation for Key Phase 2 Invikafusp Alfa Data in PD-1–Resistant Solid Tumors and Appoints Pembrolizumab Development Leader Eric Rubin, M.D., to Scientific Advisory B... | Updated STARt-001 results will highlight invikafusp alfa's single-agent activity in PD-1–resistant tumors using a biomarker-enrichment strategy
Eric Rubin, former Senior Vice President of Global Clinical Oncology at Merck, who led the initi... |
| 14.07.2026 | Phase II Trial of Cadonilimab(PD-1/CTLA-4) Combination Regimen Launches in the United States for Perioperative Treatment of Gastric Cancer | HONG KONG, July 14, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that it has entered into a collaboration with Memorial Sloan Kettering Cancer Center (MSKCC) to advance a Phase II... |
| 09.07.2026 | Upright Revolution: Leo Cancer Care Secures $65M, Reshapes Oncology Landscape | Leo Cancer Care landed $65M Series D funding. The company revolutionizes cancer treatment. It uses an integrated upright platform for radiation therapy and imaging. Patients sit for treatment, enhancing comfort and consistency. This technol... |
| 08.07.2026 | Leo Cancer Care Raises $65 Million Series D To Scale Upright Cancer Care Platform | Leo Cancer Care announced the close of an oversubscribed $65 million Series D financing round. The round was led by Yu Galaxy, with new investor Eventide Asset Management joining alongside continued support from existing investors.
Leo Canc... |
| 08.07.2026 | Leo Cancer Care Raises $65M Series D to Scale Its Integrated Upright Cancer Care Platform | Leo Cancer Care, the medical technology company working to reinvent how patients are imaged and treated by designing systems around the body’s natural upright position, today announced the close of an oversubscribed $65 million Series D fin... |
| 01.06.2026 | Experimental pill promises new hope for deadly pancreatic cancer | Getting your Trinity Audio player ready...
By LAURAN NEERGAARD
WASHINGTON (AP) — A novel pill helped people with advanced pancreatic cancer live longer, researchers reported Sunday, raising hopes of long-needed better treatments for one of ... |
| 29.05.2026 | Menarini Group Presents New Data from the Phase 1b/2 ELEVATE Study of Elacestrant in Combination with Capivasertib in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2026 American Socie... | Encouraging safety and preliminary efficacy analysis from the elacestrant and capivasertib Phase 1b regimen of the ELEVATE study will be presented.
The efficacy data highlight how the combination of elacestrant and capivasertib has the pote... |
| 17.05.2026 | Istituto Nazionale Tumori IRCCS Fondazione G. Pascale Selects MEVION S250-FIT™ for Southern Italy’s First Proton Therapy Center | Mevion Medical Systems, the global leader in compact proton therapy, today announced that it has been selected to deliver the MEVION S250-FIT Proton Therapy System™ to Istituto Nazionale Tumori IRCCS Fondazione G. Pascale in Naples. The awa... |
| 07.05.2026 | Pershing Square Sohn Cancer Research Alliance Doubles Funding Commitment, Awarding 13 Innovators In Cancer Research | The Pershing Square Sohn Cancer Research Alliance, a program of The Pershing Square Foundation, has announced 13 winners of the 2026 Pershing Square Sohn Cancer Prize, marking a transformative expansion of the program from a regional initia... |
| 24.03.2026 | Aveta Biomics Announces Podium Presentation of Registrational Phase 3 Head and Neck Cancer Trial at AHNS 2026 Conference | Global Phase 3 study of first oral immunotherapy designed to work independent of PD-L1 across “hot” and “cold” tumors in locally advanced head and neck cancer BEDFORD, MA, UNITED STATES, March 24, 2026 /EINPresswire.com/ -- Aveta Biomics, a... |
| 10.03.2026 | C-Further Unveils First Therapeutic Programmes Dedicated to Paediatric Oncology | C-Further, an international consortium committed to creating new therapeutics for childhood cancers, today unveils the first early-stage therapeutic programmes for its pipeline, dedicated to paediatric oncology indications. Through its coll... |
| 17.02.2026 | US Cancer Institute studying ivermectin’s ‘ability to kill cancer cells’ | Getting your Trinity Audio player ready...
By Rachana Pradhan, KFF Health News
The National Cancer Institute, the federal research agency charged with leading the war against the nation’s second-largest killer, is studying ivermectin as a p... |
| 19.11.2025 | Better treatments buoy multiple-myeloma patients, bound by research cuts and racial disparities | Getting your Trinity Audio player ready...
By Melba Newsome, KFF Health News
For more than a year, Diane Hunter, now 72, had been experiencing vague symptoms — pain in her spine and hips, nausea, exhaustion, thirst, and frequent urination. ... |
| 23.10.2025 | APHON Announces 2025-2026 Board of Directors and Officers | The Association of Pediatric Hematology/Oncology Nurses (APHON) proudly announces the installation of its 2025–2026 officers and directors during the Annual Business Meeting held at the 49th Annual Conference and Exhibit in Providence, Rhod... |
| 21.10.2025 | HLTH 2025 Day 1 Summary & Insights: AMA Launches AI Governance Center, Google Cloud, Microsoft, ChatGPT for Medicine | Core Clinical & Diagnostic Innovations
Real-World Evidence (RWE) Agent Pilot: Atropos Health, in collaboration with Microsoft, is piloting the Atropos Evidence™ Agent at Stanford Health Care. This expert agent generates patient-specific... |
| 10.10.2025 | I Want A New Drug. A Vaccine Even. And A Functioning FDA, CDC, NIH, Etc… | My cancer is back. This is disappointing but not unexpected; of the 2/3 of people who survive their first bout with ovarian cancer, 80% usually have it recur at some point. For me it was sooner than expected, and disheartening because, even... |
| 07.10.2025 | Predicta Biosciences: $23.4 Million Series A Raised To Advance Diagnostic And Therapeutic Discovery Tools | Predicta Biosciences, a precision oncology company focused on developing advanced diagnostic and therapeutic discovery tools, has announced the close of a $23.4 million Series A funding round. The funding round was oversubscribed and led by... |
| 02.10.2025 | Predicta Biosciences Raises $23.4M in Series A Funding | Predicta Biosciences, a Cambridge, MA-based precision oncology company developing novel diagnostic and therapeutic discovery solutions, raised $23.4m in Series A funding.
The round was led by Engine Ventures with particiaption from Illumina... |
| 23.09.2025 | Spongies Comfort Launches The Heart Armrest: A Simple Innovation Transforming Patient Experience at Leading Hospitals | The Heart Armrest is designed to bring comfort and relief during medical procedures.
Already adopted by Stanford Health Care, UCLA, UCSF, Kaiser Permanente, and over 50 IV clinics nationwide, this new medical-grade cushion improves patient ... |
| 08.08.2025 | Blood-based test provides new diagnostic approach for multiple myeloma | Researchers at Dana-Farber Cancer Institute, Massachusetts General Hospital (MGH), and the Broad Institute have developed a blood test that could transform the diagnosis and monitoring of multiple myeloma (MM) and its precursor conditions. ... |
| 05.08.2025 | SITC Announces 2025 Class of Fellows to the Academy Of Immuno-Oncology | Academy of Immuno-Oncology
The Society for Immunotherapy of Cancer (SITC) proudly announces the 2025 Class of Fellows of the Academy of Immuno-Oncology (FAIO). This year's distinguished class will be formally inducted during a special cerem... |
| 02.08.2025 | Genomics points to potential targeted treatment options for pediatric gliomas | A collaborative study between Dana-Farber Cancer Institute and the Broad Institute found that 8.9 percent of children with glioma, the most common form of pediatric brain tumor, have alterations in the fibroblast growth factor receptor (FGF... |
| 29.07.2025 | Society for Immunotherapy of Cancer Announces 2025 Annual Award Recipients | Society for Immunotherapy of Cancer
The Society for Immunotherapy of Cancer (SITC) is proud to recognize individuals who have made outstanding contributions to the field of immuno-oncology. SITC is pleased to announce the recipients of its ... |
| 08.07.2025 | Moore Wins 12 Direct Marketing Association of Washington 2025 MAXI Awards | Moore logo
The 2025 MAXI Award wins reflect Moore's commitment to strategy-led, results-driven work.
WASHINGTON, July 8, 2025 /PRNewswire-PRWeb/ -- Moore, a leading constituent experience management company, is proud to announce it has rece... |
| 03.07.2025 | ‘Not accountable to anyone’: As insurers issue denials, some patients run out of options | Recent federal and state efforts, as well as changes undertaken by insurance companies themselves, have attempted to improve a 50-year-old system that disproportionately burdens some of the sickest patients at the worst times. And yet many ... |
| 03.07.2025 | Dizal's ZEGFROVY® (sunvozertinib) Receives FDA Accelerated Approval as the Only Targeted Oral Treatment for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations | ZEGFROVY is the only approved targeted oral treatment for NSCLC with EGFR exon20ins
Approval follows the U.S. FDA's Priority Review and is supported by the pivotal WU-KONG1 Part B study, in which ZEGFROVY demonstrated statistically signific... |
| 21.05.2025 | Genomic score predicts patients' progression to multiple myeloma | A new risk assessment score developed by researchers at Dana-Farber Cancer Institute, the Broad Institute of MIT and Harvard, and Massachusetts General Hospital reveals how multiple myeloma, a form of blood cancer, begins and progresses fro... |
| 14.05.2025 | Duration of Overweight/Obesity During Treatment Linked to Worse Outcomes in Pediatric Leukemia Patients | Drs. Kara Kelly, left, and Song Yao of Roswell Park Comprehensive Cancer Center are senior authors on a new study on the impact of overweight and obesity on children with one form of leukemia.
New research in children diagnosed with acute l... |
| 22.04.2025 | Circle Pharma to Present Late-Breaking Data at AACR 2025 Demonstrating Mechanism of Action for Novel Cyclin A/B RxL Inhibitors | SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–April 22, 2025–
Circle Pharma, a clinical-stage biopharmaceutical company focused on developing cell-permeable macrocycle therapeutics, today announced a late-breaking poster presentation at the A... |
| 02.04.2025 | Artis BioSolutions Raises Funding; Acquires Landmark Bio | Artis BioSolutions, a San Diego, CA-based company which specializes in the development and production of genetic medicines, raised an undisclosed amount in funding.
The round was led by Oak HC/FT.
The company intends to use the funds to fur... |
| 12.01.2025 | Prudentia Sciences: AI-Based Life Sciences Marketplace Company Raises $7 Million | Prudentia Sciences, an AI-based technology platform for life sciences, announced its public launch, supported by $7 million in funding. This funding round was led by GV, with participation from Iaso Ventures and Virtue.
The company aims to ... |
| 11.01.2025 | Prudentia Sciences: A New Dawn in Life Sciences Dealmaking | In the bustling corridors of Cambridge, Massachusetts, a new player is making waves in the life sciences arena. Prudentia Sciences has emerged with a mission: to revolutionize how biopharma companies navigate the complex world of drug devel... |
| 09.01.2025 | Prudentia Sciences Launches with $7M in Funding to Transform the Life Sciences Marketplace for Dealmaking | CAMBRIDGE, Mass.–(BUSINESS WIRE)–January 9, 2025–
Prudentia Sciences, an AI-powered technology platform for life sciences announced today its public launch, supported by $7 million in funding. The funding round was led by GV, with participa... |
| 27.12.2024 | Ascentage Pharma to Present at 43rd Annual J.P. Morgan Healthcare Conference | ROCKVILLE, Md. and SUZHOU, China, Dec. 27, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily... |
| 24.12.2024 | Tolerance Bio: $20.2 Million (Seed) Raised To Develop Approaches To Increase Healthspan | Tolerance Bio – a biopharmaceutical company pioneering approaches to increasing healthspan by preserving, restoring, and manipulating the function of the thymus, the master regulator of immune tolerance – announced the formation of its Scie... |
| 21.12.2024 | Vintage Philanthropy: Hollander Foundation Pours $25,000 into Prostate Cancer Research from Wine-Making Proceeds | The Hollander Foundation
Dr. Franklin Huang, a physician-scientist and medical oncologist who cares for patients with prostate cancer.
The Hollander Foundation, dedicated to supporting prostate cancer research, awarded its annual gift to Fr... |
| 12.12.2024 | Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer | ADELA, an international phase III study being conducted across multiple countries, combines elacestrant with everolimus to treat advanced ER+/HER2- breast cancer with ESR1 mutations, aiming to delay disease progression.
The study was presen... |
| 11.12.2024 | Ascentage Pharma's Lisaftoclax: A Beacon of Hope in Hematologic Malignancies | In the world of hematologic malignancies, the search for effective treatments often feels like navigating a dense fog. Patients with conditions like myelodysplastic syndrome (MDS) and multiple myeloma (MM) face a daunting landscape of limit... |
| 11.12.2024 | Olverembatinib: A Beacon of Hope in Chronic Myeloid Leukemia Treatment | In the ever-evolving landscape of cancer treatment, chronic myeloid leukemia (CML) presents a formidable challenge. Traditional therapies often falter, leaving patients in a desperate search for alternatives. Enter olverembatinib, a third-g... |
| 10.12.2024 | Live from ASH 2024 | Ascentage Pharma's Bcl-2 Inhibitor Lisaftoclax in Combinations Demonstrates Potential Clinical Benefit in Patients with Prior Exposure to Venetoclax | ROCKVILLE, Md. and SUZHOU, China, Dec. 10, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily... |
| 10.12.2024 | Live from ASH 2024 | First Dataset of Olverembatinib as Second-Line Therapy in Patients with Non-T315I-Mutant CP-CML Presented in Oral Report | ROCKVILLE, Md. and SUZHOU, China, Dec. 10, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily... |
| 10.12.2024 | Live from ASH 2024 | Ascentage Pharma Releases Updated Data of Bcl-2 Inhibitor Lisaftoclax in MDS that Demonstrates Potential Clinical Benefits and Favorable Safety | ROCKVILLE, Md. and SUZHOU, China, Dec. 10, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily... |
| 10.12.2024 | Live from ASH 2024 | 1.5-Year Follow-Up Data from a Global Study of Olverembatinib Reaffirms Potential in Overcoming Resistance/Intolerance to Ponatinib or Asciminib | ROCKVILLE, Md. and SUZHOU, China, Dec. 10, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily... |
| 10.12.2024 | Live from ASH 2024 | Oral Report Features Encouraging Data of Ascentage Pharma's Bcl-2 Inhibitor Lisaftoclax in R/R MM, Including a Median PFS Over 9 Months | ROCKVILLE, Md. and SUZHOU, China, Dec. 10, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily... |
| 04.12.2024 | Tomorrow's Promise, Today's Roswell Park: Leaders Tackling the Biggest Priorities in Cancer Care and Treatment | From left to right, Candace S. Johnson, PhD, Cameron Nolan, Roswell Park nurse , and Michael Wong, MD, PhD, FRPC,
Roswell Park President and CEO Candace S. Johnson, PhD, today introduced the cancer center's first Physician in Chief — and th... |
| 25.11.2024 | Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors | ROCKVILLE, Md. and SUZHOU, China, Nov. 25, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily ... |
| 17.11.2024 | Ascentage Pharma Announces a New Drug Application for Its Novel Bcl-2 Inhibitor Lisaftoclax Accepted and Recommended Priority Review Designation by CDE of China NMPA | ROCKVILLE, Md. and SUZHOU, China, Nov. 17, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily ... |
| 04.11.2024 | Crowdfunded Wine-Making Supports Prostate Cancer Research - Drinking Charitably | Syrah grapes destined for the #2red Syrah-based Rhone-style blend
Tax-deductible crowd funded wine-making at 2redWinery supports prostate cancer research while backers receive award-winning wines.
GAINESVILLE, Fla., Nov. 4, 2024 /PRNewswire... |
| 30.10.2024 | Clinical Late-Breaking Abstracts Announced for the Society for Immunotherapy of Cancer's 39th Annual Meeting | SITC 2024 Logo
The Society for Immunotherapy of Cancer (SITC) received an incredible number of abstract submissions in 2024, more than 1,500, including a record-breaking number of clinical based Late-breaking Abstracts. SITC is proud to ann... |
| 24.10.2024 | HigherVisibility Wins Best B2B Search Marketing Initiative for SEO at Search Engine Land Awards 2024 | HigherVisibility
HigherVisibility has been named the Best B2B Search Marketing Initiative for SEO at the Search Engine Land Awards 2024.
MEMPHIS, Tenn., Oct. 24, 2024 /PRNewswire-PRWeb/ -- HigherVisibility, a leading digital marketing agenc... |
| 17.10.2024 | invIOs Secures €8.2 Million to Propel Cancer Therapies Forward | In the world of biotechnology, funding is the lifeblood that keeps innovation alive. On October 15, 2024, invIOs GmbH, a Vienna-based biotech firm, announced a significant boost to its ambitions in cancer treatment. The company raised €8.2 ... |
| 16.10.2024 | The Value of edX Certificates: Are They Worth Your Investment? | In the digital age, education has transformed. Online platforms like edX have become the new classrooms. They offer courses from prestigious institutions like Harvard and MIT. But are edX certificates worth the money? Let’s dive into the de... |
| 15.10.2024 | Circle Pharma Announces First Patients Dosed in Phase 1 Clinical Trial of First-in-Class Oral Cyclin A/B RxL Inhibitor CID-078 for Advanced Solid Tumors | SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–October 15, 2024–
Circle Pharma, Inc., a clinical-stage biopharmaceutical company dedicated to discovering and developing a new generation of macrocycle therapies, announced today that the first p... |
| 15.10.2024 | invIOs Raises €8.2M in Series A Funding | invIOs GmbH, a Vienna, Austria-based biotechnology company developing novel therapies for cancer, raised €8.2m in Series A funding.
Backers included existing shareholders and Ligand Pharmaceuticals, which recently acquired APEIRON, the form... |
| 08.10.2024 | Registrational Phase III Studies of APG-2449 Cleared by China CDE for the Treatment of Patients with NSCLC | ROCKVILLE, Md. and SUZHOU, China, Oct. 8, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily f... |
| 14.09.2024 | Live from ESMO 2024 | Ascentage Pharma Releases Latest Data Showing Sustained Clinical Efficacy of Olverembatinib in SDH-Deficient GIST during a Mini Oral Presentation | ROCKVILLE, Md. and SUZHOU, China, Sept. 14, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily... |
| 12.09.2024 | Navigating the Healthcare Supply Chain: A Balancing Act of Efficiency and Care | The healthcare supply chain is a complex web, often fraught with challenges. As hospitals and healthcare organizations grapple with rising costs and the need for efficiency, innovative solutions are emerging. One such solution is symplr, a ... |
| 12.09.2024 | 2024 Blavatnik National Awards for Young Scientists Announced | A molecular biologist from Dana-Farber Cancer Institute, a chemical engineer from US Berkeley, and an earth scientist from Cornell University are this year's Laureates.
NEW YORK, Sept. 12, 2024 /PRNewswire/ -- For the second time, the Blava... |
| 11.09.2024 | Pioneering Cancer Treatments Take Center Stage at ESMO 2024 | The European Society of Medical Oncology (ESMO) Congress 2024 is set to be a pivotal event in the world of oncology. From September 13 to 17, Barcelona will host a gathering of minds, all focused on the latest breakthroughs in cancer treatm... |
| 10.09.2024 | Brigham and Women's Hospital Nurses Vote to Ratify New Contract that Averted Potential Strike and Seeks to Improve Nurse Staffing and Patient Care Conditions | Brigham nurses negotiated a new MNA contract last month following a 99.4% strike authorization vote motivated by nurses calling on MGB to invest in nurses and improve patient safety
BOSTON, Sept. 10, 2024 /PRNewswire/ -- The 4,000 Brigham a... |
| 10.09.2024 | Datopotamab Deruxtecan Does Not Meet Its Secondary Primary Endpoint in TROPION-Lung01 | Dr. Jacob Sands, Dana-Farber Cancer Institute in Boston, Mass.
The therapy datopotamab deruxtecan did not meet its secondary dual primary end point of overall survival for patients with advanced non-small cell lung cancer but it did show a ... |
| 09.09.2024 | ESMO 2024 | Ascentage Pharma to Present Updated Data of Olverembatinib in Patients with SDH-Deficient GIST during a Mini Oral Presentation at the 2024 ESMO Congress | ROCKVILLE, Md. and SUZHOU, China, Sept. 9, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing both first-in-class and best-in-class therapies for malign... |
| 05.09.2024 | Hoth Therapeutics Announces Expansion of Clinical Sites for HT-001 Phase 2a Trial | Dana-Farber Cancer Institute in Boston, MA and Montefiore Medical Center in New York, NY Join Clinical Trial
NEW YORK, Sept. 5, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today ... |
| 20.08.2024 | The Battle for Truth: Navigating the Landscape of Cancer Research and Disinformation | In the realm of cancer research, hope is a beacon. The Society for Immunotherapy of Cancer (SITC) shines that light brightly. Their recent announcement of fellowship recipients is a testament to the commitment to innovation and progress. Wi... |
| 19.08.2024 | Society for Immunotherapy of Cancer Forward Fund Announces Recipients of Cancer Immunotherapy Fellowships | SITC Logo
In its mission to make "cure" a reality for cancer patients everywhere and support the development of early career investigators, the Society for Immunotherapy of Cancer (SITC) Forward Fund is pleased to announce the rec... |
| 17.08.2024 | Red Queen Therapeutics: A New Dawn in Antiviral Innovation | In the ever-evolving landscape of viral threats, Red Queen Therapeutics emerges as a beacon of hope. Armed with a $55 million Series A funding from Apple Tree Partners, this clinical-stage biotechnology company is on a mission to revolution... |
| 16.08.2024 | Red Queen Therapeutics: $55 Million (Series A) Closed To Develop Novel Antiviral Treatments | Apple Tree Partners (ATP) – a leader in life sciences venture capital – has unveiled Red Queen Therapeutics, a clinical-stage biotechnology company developing novel antiviral treatments for the general population and especially for immunoco... |
| 13.08.2024 | Registrational Phase III Study of Lisaftoclax in Newly-Diagnosed Patients with Higher-Risk Myelodysplastic Syndrome Cleared by China CDE | ROCKVILLE, Md. and SUZHOU, China, Aug. 13, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global, integrated biopharmaceutical company engaged in discovering, developing and commercializing both first- and best-in-class therapies for ma... |
| 09.08.2024 | The New Face of Cancer: Rising Rates Among the Young and the Role of AI in Treatment | Cancer has long been viewed as a disease of the elderly. However, recent studies reveal a startling shift. Young people are increasingly falling prey to various cancers, a trend that raises urgent questions about environmental factors and l... |
| 08.08.2024 | Commentary: Rising rates of cancer in young people prompt hunt for environmental culprit | LONDON: The idea of cancer as predominantly a disease of old age is beginning to creak. An analysis last year showed that, in the Group of Twenty ( G20) industrialised nations, rates of several cancers are rising faster among the young than... |
| 08.08.2024 | MNA: Brigham and Women's Hospital Nurses Avert Potential 1-Day Strike, Reaching Tentative Agreement Aimed at Addressing Unsafe Staffing and Improving Patient Care Conditions | Brigham nurses negotiated a new tentative MNA contract on August 8 after voting 99.4% to authorize a one-day strike after nurses called on MGB to invest in nurses and improve patient safety
BOSTON, Aug. 8, 2024 /PRNewswire/ -- The nearly 4,... |
| 05.08.2024 | SITC Announces 2024 Class of Fellows to the Academy of Immuno-Oncology | Academy of Immuno-Oncology
The Society for Immunotherapy of Cancer (SITC) announces the 2024 Class of Fellows of the Academy of Immuno-Oncology (FAIO). The luminaries of the 2024 class will be inducted at an event during SITC's 39th Annual ... |
| 03.08.2024 | The Pan-Mass Challenge Cycles Beyond $1 Billion in Lifetime Fundraising for Cancer Research in 45 Years | World's Single Most Successful Athletic Fundraiser Aims to Raise Unprecedented $75 million in 2024
BOSTON, August 3, 2024 /PRNewswire/ -- On Saturday, August 3, and Sunday, August 4, the Pan-Mass Challenge (PMC) will bring together thousand... |
| 29.07.2024 | Predicta Biosciences: Pioneering a New Era in Cancer Diagnostics | Predicta Biosciences is making waves in the ocean of cancer diagnostics. With a fresh infusion of $5.2 million in seed funding, this Boston-based precision oncology company is poised to change the landscape of how we detect and treat blood ... |
| 27.07.2024 | Predicta Biosciences Raises $5.2 Million To Develop Novel Diagnostic And Therapeutic Products | Predicta Biosciences, a precision oncology company developing novel diagnostic and therapeutic products, announced it had raised an oversubscribed $5.2 million seed round led by The Engine Ventures. And additional participating investors in... |
| 19.07.2024 | Dana-Farber Cancer Institute Nurses Have Voted to Ratify New MNA Contract Featuring Significant Investment in Nursing and Patient Care | Registered nurses and nurse practitioners voted overwhelmingly to finalize an agreement reached in June to help DFCI recruit and retain the nurses needed to provide world-class cancer care
BOSTON, July 19, 2024 /PRNewswire/ -- The almost 80... |
| 11.07.2024 | Myeloma Investment Fund Invests in Dynamic Cell Therapies to Help Fuel Novel CAR-T-Cell Technologies | WATERTOWN, Mass., July 11, 2024 /PRNewswire/ -- Dynamic Cell Therapies (DCT) announces an investment of $1M from the Myeloma Investment Fund (MIF), the venture philanthropy subsidiary of the Multiple Myeloma Research Foundation (MMRF), to a... |
| 08.07.2024 | Olverembatinib Approved for Commercialization in Macau China | ROCKVILLE, Md. and SUZHOU, China, July 8, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing both first- and best-in-class therapies for hematological m... |
| 04.07.2024 | Ascentage Pharma Received US$100 Million Option Payment from Takeda | ROCKVILLE, Md. and SUZHOU, China, July 4, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing both first-in-class and best-in-class therapies for hematol... |
| 02.07.2024 | MGB Home Care Nurses and Healthcare Professionals Vote to Join MNA as they Seek an Independent Voice to Improve Safety for Patients and Staff | MGB Home Care clinicians plan to use their collective strength as union members to secure professional respect and ensure safe patient care conditions
BOSTON, July 2, 2024 /PRNewswire/ -- Mass General Brigham (MGB) Home Care nurses and heal... |
| 01.07.2024 | Stamford Health Announces Opening of Harbor Point Walk-In Center | STAMFORD, Conn., July 1, 2024 /PRNewswire/ -- Today, Stamford Health announced the opening of the Harbor Point Walk-In Center, which will begin offering family medicine walk-in services immediately. The facility, located at 170 Washington B... |
| 21.06.2024 | Ascentage Pharma Announces Closing of US$75 Million Equity Investment by Takeda | ROCKVILLE, Md. and SUZHOU, China, June 21, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced ... |
| 18.06.2024 | Live from EHA 2024 | Ascentage Pharma Releases Updated Data of Lisaftoclax in Patients with R/R MM and AL Amyloidosis Highlighting Marked Improvement in ORR | SUZHOU, China and ROCKVILLE, Md., June 18, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced ... |
| 11.06.2024 | Global Registrational Phase III Study of Olverembatinib for the Treatment of Patients with SDH-Deficient GIST Approved by the China CDE | SUZHOU, China, and ROCKVILLE, Md., June 11, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced... |
| 11.06.2024 | Dr. John A. Abraham, Nationally Recognized Orthopaedic Oncologist, Opens Office in Marlton, New Jersey | Abraham Orthopaedics is thrilled to announce the opening of its newest office in Marlton, New Jersey, serving the entire South Jersey region. The practice is led by the distinguished Dr. John A. Abraham, a nationally recognized orthopaedic ... |
| 05.06.2024 | Live from ASCO 2024 | Ascentage Pharma Releases Updated Data Showing Promising Efficacy and Safety of Lisaftoclax in Patients with WM | SUZHOU, China, and ROCKVILLE, Md., June 5, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced ... |
| 05.06.2024 | Live from ASCO 2024 | Oral Report Released Latest Data of Olverembatinib in SDH-Deficient GIST, Including a CBR of 92.3% | SUZHOU, China and ROCKVILLE, Md., June 5, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced t... |
| 04.06.2024 | Live from ASCO 2024 | Updated Data of Bcl-2 Inhibitor Lisaftoclax Combined with Azacitidine in Patients with AML Demonstrate Promising Efficacy and Manageable Safety | SUZHOU, China and ROCKVILLE, Md., June 4, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced t... |
| 22.05.2024 | Breakthrough Properties to Welcome Three Mission-Driven Biotech Companies to One Canal Development in the Heart of Cambridge | Leases with Deep Genomics, Larkspur Biosciences and Incendia Therapeutics Executed Upon Substantial Construction Completion, Anchoring Breakthrough's East Cambridge Waterfront Building
BOSTON, May 22, 2024 /PRNewswire/ -- Breakthrough Prope... |
| 16.05.2024 | EHA 2024 | Results from Five Studies of Ascentage Pharma's Key Drug Candidates Selected for Presentations at 2024 European Hematology Association Hybrid Congress | SUZHOU, China and ROCKVILLE, Md., May 16, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced t... |
| 04.05.2024 | Anthropic's Claude Teams and iOS App Revolutionize Enterprise AI Adoption | Anthropic is leading the charge in responsible AI integration for businesses. With the release of Claude Teams and the new iOS app, the company is making waves in the industry. Discover how these innovations are changing the game for enterp... |
| 01.05.2024 | Anthropic’s Claude Teams and iOS App: The secure, scalable solution for enterprise AI adoption | Discover how companies are responsibly integrating AI in production. This invite-only event in SF will explore the intersection of technology and business. Find out how you can attend here.
Anthropic, a startup at the forefront of developin... |
| 25.04.2024 | ASCO 2024 | Ascentage Pharma to Present Four Studies, Including an Oral Report Featuring the Latest Data of Olverembatinib in SDH-Deficient GIST | SUZHOU, China and ROCKVILLE, Md., April 25, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced... |
| 22.04.2024 | AccessHope Secures $33M to Expand Cancer Care Expertise | What You Should Know:
– AccessHope, a company revolutionizing how cancer patients receive cutting-edge treatment plans secures $33M in a Series B funding round led by City of Hope, a prominent cancer research and treatment organization.
– T... |
| 20.04.2024 | The Melanoma Research Foundation to host the New England Miles for Melanoma 5K | New England Miles for Melanoma
The Melanoma Research Foundation (MRF) is thrilled to announce one of the first events in its annual Miles for Melanoma nationwide 5K program, bringing together local melanoma patients, care partners and thriv... |
| 17.04.2024 | National Comprehensive Cancer Network Awards Champions for Excellence and Outstanding Contributions in Cancer Care | Dr. Shaji Kumar, Darcie Green, and members of the NCCN Covid-19 Vaccine Advisory Committee honored for their contributions to improving cancer care over the years; Donna Black named NCCN Employee of the Year.
PLYMOUTH MEETING, Pa., April 17... |
| 16.04.2024 | Innovent Announces the Appointment of Dr. Nageatte Ibrahim as the Oncology Chief Medical Officer (CMO) | SAN FRANCISCO and SUZHOU, China, April 16, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for... |
| 08.04.2024 | AACR 2024 | Ascentage Pharma Presents Results from Three Studies at 2024 American Association of Cancer Research Annual Meeting | ROCKVILLE, Md. and SUZHOU, China, April 8, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, age-related diseases, and chronic hepatitis B (CHB), announced ... |
